Syntarga

Cancer-Fighting Medicines

Syntarga BV, a spin off of the Radboud University in Nijmegen, has developed a new technology in order to bind antibodies to cancer medicines. This patented technology can also be used to develop new kinds of targeted cancer-fighting medicines.

What is unique regarding this technology is that it uses antibodies to recognize tumor tissue. In order to eliminate the cancer cells, these antibodies – via the link with Syntarga – bind with the chemotherapeutic material that will eventually also be developed by the company. Through the release of substances by the cancer tumor, the separate parts come together in combination with exactly the right chemical balance that is effective in fighting cancer. There are few, if any, side effects. The combination of antibodies and cancer drugs is called “Antibody Drug Conjugate,” or ADC.

Investing in a health future

PPM Oost invested in Syntarga in order for them to develop an effective drug to fight cancer. We sold our interest in the company in 2011. Syntarga was subsequently taken over by Synthon, a company with more than 1,300 employees spread across 11 international locations. Synthon is one of the leading players in the world market for generic drugs. Both Syntarga and Synthon were established and developed at the Radboud University of Nijmegen. The university continues to be a breeding ground of medical innovation and dynamic entrepreneurism.

www. syntarga .com